Werewolf Therapeutics Stock Performance
| HOWL Stock | USD 1.46 0.05 3.55% |
On a scale of 0 to 100, Werewolf Therapeutics holds a performance score of 12. The firm maintains a market beta of 2.59, which attests to a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Werewolf Therapeutics will likely underperform. Please check Werewolf Therapeutics' value at risk, as well as the relationship between the skewness and day median price , to make a quick decision on whether Werewolf Therapeutics' historical returns will revert.
Risk-Adjusted Performance
Good
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Werewolf Therapeutics are ranked lower than 12 (%) of all global equities and portfolios over the last 90 days. Despite quite weak basic indicators, Werewolf Therapeutics disclosed solid returns over the last few months and may actually be approaching a breakup point. ...more
1 | Acquisition by Bloom Steven H. of 201720 shares of Werewolf Therapeutics at 0.87 subject to Rule 16b-3 | 05/01/2025 |
2 | Werewolf Therapeutics Showcases Innovative IBD Treatment Developments HOWL Stock News | 05/05/2025 |
3 | Acquisition by Ra Capital Management, L.p. of 320913 shares of Werewolf Therapeutics at 0.86 subject to Rule 16b-3 | 05/12/2025 |
4 | Werewolf Therapeutics to Participate in Hanson Wades 6th Annual Cytokine-Based Drug ... | 05/13/2025 |
5 | Acquisition by Ra Capital Management, L.p. of 1625 shares of Werewolf Therapeutics at 0.98 subject to Rule 16b-3 | 05/14/2025 |
6 | Werewolf Therapeutics, Inc. Director Ra Capital Management, L.P. Acquires 320,913 Shares | 05/15/2025 |
7 | HonorHealth Research Institute patient with advanced skin cancer in remission for more than a year following clinical trial of Werewolf Therapeutics investigati... | 05/20/2025 |
8 | Werewolf Therapeutics to Participate in the Upcoming Jefferies Global Healthcare Conference | 05/29/2025 |
9 | Acquisition by Singhal Anil K. of 9000 shares of Werewolf Therapeutics at 1.23 subject to Rule 16b-3 | 06/11/2025 |
10 | Werewolf Therapeutics Adopts New Bylaws and Elects Directors - TipRanks | 06/13/2025 |
11 | Werewolf Therapeutics to Participate in the KidneyCAN 7th Annual Kidney Cancer Research Summit | 07/09/2025 |
| Begin Period Cash Flow | 155.6 M | |
| Total Cashflows From Investing Activities | -254 K |
Werewolf Therapeutics Relative Risk vs. Return Landscape
If you would invest 87.00 in Werewolf Therapeutics on April 22, 2025 and sell it today you would earn a total of 54.00 from holding Werewolf Therapeutics or generate 62.07% return on investment over 90 days. Werewolf Therapeutics is currently generating 0.9586% in daily expected returns and assumes 6.1425% risk (volatility on return distribution) over the 90 days horizon. In different words, 55% of stocks are less volatile than Werewolf, and 81% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Werewolf Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Werewolf Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Werewolf Therapeutics, and traders can use it to determine the average amount a Werewolf Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.1561
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | HOWL | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 6.14 actual daily | 55 55% of assets are less volatile |
Expected Return
| 0.96 actual daily | 19 81% of assets have higher returns |
Risk-Adjusted Return
| 0.16 actual daily | 12 88% of assets perform better |
Based on monthly moving average Werewolf Therapeutics is performing at about 12% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Werewolf Therapeutics by adding it to a well-diversified portfolio.
Werewolf Therapeutics Fundamentals Growth
Werewolf Stock prices reflect investors' perceptions of the future prospects and financial health of Werewolf Therapeutics, and Werewolf Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Werewolf Stock performance.
| Return On Equity | -0.83 | ||||
| Return On Asset | -0.33 | ||||
| Operating Margin | (65.11) % | ||||
| Current Valuation | 8.24 M | ||||
| Shares Outstanding | 44.87 M | ||||
| Price To Earning | 0.84 X | ||||
| Price To Book | 1.10 X | ||||
| Price To Sales | 55.36 X | ||||
| Revenue | 1.89 M | ||||
| Gross Profit | (52.24 M) | ||||
| EBITDA | (64.05 M) | ||||
| Net Income | (70.52 M) | ||||
| Cash And Equivalents | 145.71 M | ||||
| Cash Per Share | 4.93 X | ||||
| Total Debt | 37.09 M | ||||
| Debt To Equity | 0.12 % | ||||
| Current Ratio | 5.08 X | ||||
| Book Value Per Share | 1.28 X | ||||
| Cash Flow From Operations | (56.19 M) | ||||
| Earnings Per Share | (1.64) X | ||||
| Market Capitalization | 63.27 M | ||||
| Total Asset | 126.93 M | ||||
| Retained Earnings | (414.59 M) | ||||
| Working Capital | 97.89 M | ||||
About Werewolf Therapeutics Performance
By examining Werewolf Therapeutics' fundamental ratios, stakeholders can obtain critical insights into Werewolf Therapeutics' financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that Werewolf Therapeutics is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.56) | (0.58) | |
| Return On Capital Employed | (0.66) | (0.69) | |
| Return On Assets | (0.56) | (0.58) | |
| Return On Equity | (0.96) | (0.91) |
Things to note about Werewolf Therapeutics performance evaluation
Checking the ongoing alerts about Werewolf Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Werewolf Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Werewolf Therapeutics is way too risky over 90 days horizon | |
| Werewolf Therapeutics may become a speculative penny stock | |
| Werewolf Therapeutics appears to be risky and price may revert if volatility continues | |
| Werewolf Therapeutics has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 1.89 M. Net Loss for the year was (70.52 M) with loss before overhead, payroll, taxes, and interest of (52.24 M). | |
| Werewolf Therapeutics currently holds about 145.71 M in cash with (56.19 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.93, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Roughly 63.0% of the company shares are owned by institutional investors | |
| Latest headline from gurufocus.com: Werewolf Therapeutics to Participate in the KidneyCAN 7th Annual Kidney Cancer Research Summit |
- Analyzing Werewolf Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Werewolf Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Werewolf Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Werewolf Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Werewolf Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Werewolf Therapeutics' stock. These opinions can provide insight into Werewolf Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Werewolf Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in housing. For more information on how to buy Werewolf Stock please use our How to buy in Werewolf Stock guide.You can also try the Instant Ratings module to determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Werewolf Therapeutics. If investors know Werewolf will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Werewolf Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.64) | Revenue Per Share | Quarterly Revenue Growth (1.00) | Return On Assets | Return On Equity |
The market value of Werewolf Therapeutics is measured differently than its book value, which is the value of Werewolf that is recorded on the company's balance sheet. Investors also form their own opinion of Werewolf Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Werewolf Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Werewolf Therapeutics' market value can be influenced by many factors that don't directly affect Werewolf Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Werewolf Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Werewolf Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Werewolf Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.